MedPath

Cefazolin

Generic Name
Cefazolin
Drug Type
Small Molecule
Chemical Formula
C14H14N8O4S3
CAS Number
25953-19-9
Unique Ingredient Identifier
IHS69L0Y4T
Background

A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Indication

Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis.

Associated Conditions
Bacterial Septicemia caused by susceptible Bacterial Infections, Biliary tract infection bacterial caused by susceptible Bacterial Infections, Bone and Joint Infections caused by susceptible Bacterial Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Community Acquired Pneumonia (CAP), Endocarditis caused by susceptible Bacterial Infections, Genital infection caused by susceptible Bacterial Infections, Osteoarticular Infections, Postoperative Infections, Respiratory Tract Infection Bacterial caused by susceptible Bacterial Infections, Skin and Soft Tissue Infections (SSTIs), Skin and Subcutaneous Tissue Infection caused by susceptible Bacterial Infections, Susceptible infections, Urinary Tract Infection caused by susceptible Bacterial Infections, Perioperative infection, Susceptible Bacterial Infections
Associated Therapies
Antibiotic pre-surgical prophylaxis

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

Phase 3
Terminated
Conditions
Bacteremia
Interventions
First Posted Date
2014-08-04
Last Posted Date
2020-02-17
Lead Sponsor
Cumberland Pharmaceuticals
Target Recruit Count
121
Registration Number
NCT02208063
Locations
🇺🇸

Remington-Davis Clinical Research, Columbus, Ohio, United States

Prophylactic Antibiotic in Treatment of Fingertip Amputation

Not Applicable
Completed
Conditions
Infection Rate After Fingertip Amputation
Interventions
First Posted Date
2014-03-04
Last Posted Date
2015-07-10
Lead Sponsor
HaEmek Medical Center, Israel
Target Recruit Count
60
Registration Number
NCT02077400
Locations
🇮🇱

HaEmek medical center, Afula, Israel

Increased Cefazolin During Cesarean Delivery in Obese Population

Phase 4
Completed
Conditions
Obesity
Obesity, Morbid
Infection; Cesarean Section
Pregnancy
Interventions
First Posted Date
2014-01-30
Last Posted Date
2021-02-02
Lead Sponsor
MemorialCare Health System
Target Recruit Count
30
Registration Number
NCT02049944
Locations
🇺🇸

University of California, Irvine, Orange, California, United States

🇺🇸

MemorialCare Center for Women at Miller Children's Hospital Long Beach and Long Beach Memorial Medical Center, Long Beach, California, United States

Prevention of Infection in Closed Fractures: Cefazolin Versus Vancomycin

Not Applicable
Terminated
Conditions
Infection
Closed Fractures
Interventions
First Posted Date
2014-01-06
Last Posted Date
2018-07-11
Lead Sponsor
University of Tennessee
Target Recruit Count
430
Registration Number
NCT02027532
Locations
🇺🇸

Erlanger Health System, Chattanooga, Tennessee, United States

Antibiotic Prophylaxis in Gynecologic Laparoscopy

Not Applicable
Completed
Conditions
Infection Secondary to Surgical Procedure
Interventions
Procedure: gynecologic laparoscopy
Drug: Placebo
First Posted Date
2013-11-25
Last Posted Date
2015-04-27
Lead Sponsor
Universidade do Vale do Sapucai
Target Recruit Count
114
Registration Number
NCT01991834
Locations
🇧🇷

Hospital das Clinicas Samuel Libanio, Pouso Alegre, Minas Gerais, Brazil

🇧🇷

Hospital e Maternidade Santa Paula, Pouso Alegre, Minas Gerais, Brazil

Antibiotic Prophylaxis for Revision, Clean Head and Neck Surgery

Phase 4
Completed
Conditions
Surgical Wound Infection
Interventions
Drug: Placebo
First Posted Date
2013-11-08
Last Posted Date
2018-02-08
Lead Sponsor
Rabin Medical Center
Target Recruit Count
53
Registration Number
NCT01980082
Locations
🇮🇱

Department of Otolaryngology, Rabin Medical Center, Petach Tikva, Israel

Pediatric Cefazolin PK Study

Phase 1
Completed
Conditions
Infections
Interventions
First Posted Date
2013-07-22
Last Posted Date
2017-07-21
Lead Sponsor
B. Braun Medical Inc.
Target Recruit Count
12
Registration Number
NCT01904357
Locations
🇺🇸

Toledo Children's Hospital, Toledo, Ohio, United States

🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

Peri-operative Cefazolin Prophylaxis at Time of Cesarean Delivery in the Obese Gravida

Phase 1
Completed
Conditions
Pregnancy
Obesity
Interventions
First Posted Date
2013-07-22
Last Posted Date
2014-08-18
Lead Sponsor
University of Pittsburgh
Target Recruit Count
26
Registration Number
NCT01904500
Locations
🇺🇸

Magee-Women's Hospital/University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Serum and Tissue Cefazolin Concentrations in Normal Weight Patients Undergoing Cesarean Delivery.

Phase 4
Withdrawn
Conditions
Infection
Cesarean Delivery
Antibiotic Prophylaxis
Interventions
First Posted Date
2013-06-18
Last Posted Date
2013-06-18
Lead Sponsor
West Virginia University
Registration Number
NCT01880112
Locations
🇺🇸

West Virginia University Hospital, Morgantown, West Virginia, United States

Neonatal Suspected Sepsis Treated With Cefazolin or Vancomycin

Phase 3
Completed
Conditions
Nosocomial Neonatal Sepsis
Interventions
First Posted Date
2013-06-03
Last Posted Date
2013-06-03
Lead Sponsor
Hospital Italiano de Buenos Aires
Target Recruit Count
109
Registration Number
NCT01867138
Locations
🇦🇷

Hospital Italiano de Buenos Aires, Buenos Aires, Capital, Argentina

© Copyright 2025. All Rights Reserved by MedPath